Lesion of the substantia nigra pars compacta downregulates striatal glutamate receptor subunit mRNA expression

Brain Research

Volumn 850, Issue 1-2, 1999, Pages 79-86

  Fan, Xiu Di ^a   Li, Xin Min ^a   Ashe, Paula C ^a   Juorio, Augusto V ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Dopamine; Glutamate receptor; Substantia nigra

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; GLUTAMATE RECEPTOR; MESSENGER RNA; RECEPTOR SUBUNIT; TYROSINE 3 MONOOXYGENASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DOSE RESPONSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; SUBSTANTIA NIGRA; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0032737902     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)02106-X     Document Type: Article

References (45)

1. Andén N.E., Magnusson T., Stock G. Effects of drugs influencing monoamine mechanisms on the increase in brain dopamine produced by axotomy or treatment with γ-hydroxybutyric acid. Naunyn-Schmiedeberg's Arch. Pharmacol. 278:1973;363-372.
2. Bell L.J., Iversen L.L., Uretsky N.J. Time course of the effects of 6-hydroxydopamine on catecholamine containing neurons in rat hypothalamus and striatum. Br. J. Pharmacol. 40:1970;790-799.
3. Ben-Shachar D., Zuk R., Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J. Neurochem. 64:1995;718-723.
4. Blandini F., Porter R.H.P., Greenamyre J.T. Glutamate and Parkinson's disease. Mol. Neurobiol. 12:1996;73-94.
5. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
6. Coyle J.T., Puttfarken P. Oxidative stress, glutamate and neurodegenerative disorders. Science. 262:1993;689-695.
7. Ehringer H., Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-hydroxy tyramin) im Gehirn des Menschen und ihr Verhalten bei erkrankungen des Extrapyramidalen Systems. Klin. Wochenschr. 38:1960;1236-1239.
8. Fahn S. The endogenous toxin hypothesis of the etiology of Parkinson's disease and a pilot trial of high-dosage antioxidant in an attempt to slow the progression of the illness. Ann. N. Y. Acad. Sci. 570:1989;186-196.
9. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32:1992;804-812.
10. Fan X.-D., Zhang X., Yu P.H., Li X.-M., Juorio A.V. Induction of preconvulsive behavior and Fos expression by dopamine-induced nigral lesion in the rat. Brain Res. 751:1997;31-36.
11. Fass B., Butcher L.L. Evidence for a crossed nigrostriatal pathway in rats. Neurosci. Lett. 22:1981;109-113.
12. Faull R.L.M., Laverty R. Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra. Exp. Neurol. 23:1969;332-340.
13. Fornstedt B., Brum A., Rosengren E., Carlsson A. The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J. Neural Transm. 1:1989;279-295.
14. Garside S., S Furtado J.C., Mazurek M.F. Dopamine-glutamate interactions in the striatum: behaviorally relevant modification of excitotoxicity by dopamine receptor-mediated mechanisms. Neuroscience. 75:1996;1065-1074.
15. Gasser T., Wszolek Z.K., Trofatter J. Genetic studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann. Neurol. 36:1994;387-396.
16. L. Golbe, J.W. Langston, The etiology of Parkinson's disease: new directions for research, in: J. Jankovic, E. Tolosa (Eds.), Parkinson's disease and movement disorders, Williams and Wilkins, Baltimore, 1993, pp. 93-102.
17. Graham D.G., Tiffany S.M., Bell W.R., Gutknecht W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C 1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14:1978;644-653.
18. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 59:1992;1609-1623.
19. Halliwell B., Gutteridge J.M.C. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 186:1990;1-85.
20. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64:1995;919-924.
21. Hastings T.G., Lewis D.A., Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U.S.A. 93:1996;1956-1961.
22. 3H ] dopamine: impact of ascorbic acid and glutathione J. Neurochem. 63:1994;1126-1132.
23. Hastings T.G., Zigmond M.J. Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. J. Neural. Transm. 49:1997;103-110.
24. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45:1987;19-34.
25. Javitch J.A. Theories on the etiology and pathogenesis of Parkinson's disease. Neurology. 43:1993;S21-S23.
26. Kosofsky B.E., Genova L.M., Hyman S.E. Postnatal age defines specificity of immediate early gene induction by cocaine in developing rat brain. J. Comp. Neurol. 351:1994;27-40.
27. Kwok R.S.P., Juorio A.V. The concentration of striatal tyramine and dopamine metabolism in diabetic rats and the effect of insulin administration. Neuroendocrinology. 43:1986;590-596.
28. Li X.-M., Juorio A.V., Qi J., Boulton A.A. L-deprenyl induces aromatic L-amino acid decarboxylase (AADC) mRNA in the rat substantia nigra and ventral tegmentum. An in situ hybridization study. Mol. Chem. Neuropathol. 35:1998;149-155.
29. Mattammal M.B., Haring J.H., Chung H.D., Raghu G., Strong R. An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. Neurodegeneration. 4:1995;271-281.
30. Meshul C.K., Emre N., Nakamura C.M., Allen C., Donohue M.K., Buckman J.F. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience. 88:1999;1-16.
31. Mitchell I.J., Lawson S., Moser B., Laidlaw S.M., Cooper A.J., Walkinshaw G., Waters C.M. Glutamate-induced apoptosis results in a loss of striatal neurons in the Parkinsonian rat. Neuroscience. 63:1994;1-5.
32. Parent A. Extrinsic connections of the basal ganglia. Trends Neurosci. 13:1990;254-258.
33. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, Sydney, Australia, 1982.
34. Porter R.H.P., Greene J.G., Higgins D.S., Greenamyre T. Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. J. Neurosci. 14:1994;7192-7199.
35. 3H ] 3-(2-carbodypiperazin-4-yl) propyl-l-phosphonic acid binding J. Neurochem. 54:1990;1926-1933.
36. Schneider J.S., Markham C.H. Neurotoxic effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the cat. Tyrosine hydroxylase immunohistochemistry. Brain Res. 373:1986;258-267.
37. Smith Y., Parent A. Neurons in the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity. Brain Res. 453:1988;353-356.
38. 2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse. 19:1995;264-293.
39. Stock G., Magnusson J., Andén N.E. Increase in brain dopamine after axotomy or treatment with gammahydroxybutyric acid due to elimination of impulse flow. Naunyn-Schmiedeberg's Arch. Pharmacol. 278:1973;347-361.
40. Tarazi F.J., Campbell A., Yeghiayan S.K., Baldessarini R.J. Localization of ionotropic glutamate receptors in caudate-putamen and nucleus accumbens septi of rat brain: comparison of NMDA, AMPA, and kainate receptors. Synapse. 30:1998;227-235.
41. Tremblay M., Salin P., Soghomonian J.-J. Effect of 6-OHDA lesions on striatal mRNA levels encoding for glutamate receptor subunits. NeuroReport. 6:1995;2225-2229.
42. Ulas J., Cotman C.W. Dopaminergic denervation of striatum results in elevated expression of NR2A subunit. NeuroReport. 7:1996;1789-1793.
43. Weihmuller F.B., O'Dell S.J., Marshall J.F. Alterations in striatal glutamate receptors following 6-OHDA-induced damage to nigrostriatal dopamine neurons. Soc. Neurosci. Abstr. 19:1993;1678.
44. Westerink B.H.C., van der Heyden J.A.M., Korf J. Enhanced dopamine metabolism after small lesions in the midbrain of the rat. Life Sci. 22:1978;749-756.
45. Wüllner U., Testa C.M., Catania M.V., Young A.B., Penney J.B. Glutamate receptors in striatum and substantia nigra: effects of medial forebrain bundle lesions. Brain Res. 645:1994;98-102.